Skip to main content
Premium Trial:

Request an Annual Quote

Nanogen, 600,000 Votes Shy, Seeks More Shareholder Input for Dec. 15 Merger Decision

NEW YORK, Dec. 14 (GenomeWeb News) - Nanogen needs around 600,000 shareholder votes for its special stockholder meeting on Dec. 15 to allow its merger with Epoch Biosciences to go forward, the company said today.

 

Shareholders will decide at the meeting whether to issue new shares of Nanogen common stock in connection with the merger, and whether to amend the Nanogen certificate of incorporation to expand the number of authorized shares, a prerequisite for the merger.

 

The meeting was adjourned on Dec. 8 and postponed until Dec. 15 because the number of shares represented by votes or votes by proxy was insufficient for a decision. As of now, shares represented by proxy are 600,000 votes shy of the necessary 16.7 million votes. Nanogen stockholders as of Oct. 26 are eligible for voting.

The Scan

Germline-Targeting HIV Vaccine Shows Promise in Phase I Trial

A National Institutes of Health-led team reports in Science that a broadly neutralizing antibody HIV vaccine induced bnAb precursors in 97 percent of those given the vaccine.

Study Uncovers Genetic Mutation in Childhood Glaucoma

A study in the Journal of Clinical Investigation ties a heterozygous missense variant in thrombospondin 1 to childhood glaucoma.

Gene Co-Expression Database for Humans, Model Organisms Gets Update

GeneFriends has been updated to include gene and transcript co-expression networks based on RNA-seq data from 46,475 human and 34,322 mouse samples, a new paper in Nucleic Acids Research says.

New Study Investigates Genomics of Fanconi Anemia Repair Pathway in Cancer

A Rockefeller University team reports in Nature that FA repair deficiency leads to structural variants that can contribute to genomic instability.